OJMM  Vol.3 No.4 , December 2013
Identification and Susceptibility Profile of Vaginal Candida Species to Antifungal Agents among Pregnant Women Attending the Antenatal Clinic of Thika District Hospital, Kenya
Fungal infections have emerged as a worldwide health care problem in recent years, owing to the extensive use of broad-spectrum antibiotics. We screened 104 pregnant women with symptoms of vaginal candidiasis in the antenatal clinic of Thika District Hospital, Kenya in order to identify vaginal Candida species and determine their susceptibility profile to commonly used antifungal drugs for treatment of the infection. The drugs tested were fluconazole, ketoconazole, itraconazole, clotrimazole and topical nystatin. Vaginal swabs were collected and subjected to mycological and biochemical tests for Candida species identification. Susceptibility profile of the identified vaginal Candida species to the antifungal drugs was carried out using broth micro-dilution minimum inhibiting concentration method based on the approved National Committee for Clinical Laboratory Standards (NCCLS, 2002) guidelines. Candida albicans was susceptible to most of the azoles drugs while the other species had varying responses. Candida krusei and Candida glabrata species isolated were resistant to fluconazole and ketoconazole. Candida albicans isolates had a high susceptibility to itraconazole (88.33%). Five percent (5%) of the isolates were susceptible in dose dependent (S-DD) with Minimum Inhibitory Concentrations (MICs) of 0.25 - 0.5 μg/ml while 11.67% of C. albicans isolates were resistant (MICs ≥ 1 μg/ml). Itraconazole resistance was highest among C. glabrata isolates (50%) while 32.14% were S-DD (MICs 0.25 - 0.5 μg/ml). Only 17.85% of the C. glabrata isolates were susceptible (MICs of ≤ 0.125 μg/ml). All isolates of Candida isolates were susceptible to itraconazole and clotrimazole except C. krusei which was 100% resistant to clotrimazole. All Candida species isolates had low susceptibility to topical nystatin except Candida parapsilosis that was 100% susceptible. Data also showed an emerging resistance of Candida krusei to most of the drugs used except itraconazole. The results of this study support the continued use of these antifungal drugs for the treatment of vaginal candidiasis in the pregnant women except topical nystatin.

Cite this paper
M. Nelson, W. Wanjiru and M. Margaret, "Identification and Susceptibility Profile of Vaginal Candida Species to Antifungal Agents among Pregnant Women Attending the Antenatal Clinic of Thika District Hospital, Kenya," Open Journal of Medical Microbiology, Vol. 3 No. 4, 2013, pp. 239-247. doi: 10.4236/ojmm.2013.34036.
[1]   C. Bii, T. Ouko, E. Amukoye and W. Githinji, “Antifungal Drug Susceptibility of Candida albicans,” East African Medical Journal, Vol. 79, No. 3, 2002, pp. 143-145. http://dx.doi.org/10.4314/eamj.v79i3.8894

[2]   M. Kangogo, W. Wanyoike and C. Bii, “Characterization of Candida Species from Clinical Sources in Nairobi, Kenya,” East African Medical Journal, Vol. 12, 2008, pp. 34-42.

[3]   K. Hazen, “New and Emerging Yeast Pathogens,” Clinical Microbiology, Vol. 8, 1995, pp. 462-478.

[4]   V. Kremery and A. Barnes, “Non-albicans spp. Causing Fungaemia: Pathogenicity and Antifungal Resistance,” Journal of Hospital Infection, Vol.50, 2002, pp. 243-260. http://dx.doi.org/10.1053/jhin.2001.1151

[5]   M. Pfaller and D. Diekema, “Role of Sentinel Surveillance of Candidemia. Trends in Species Distribution and Antifungal Susceptibility,” Journal of Clinical Microbiology Diseases, Vol. 40, 2002, pp. 3551-3557. http://dx.doi.org/10.1128/JCM.40.10.3551-3557.2002

[6]   J. Chander, “A Textbook of Medical Mycology,” 2nd Edition, Mehta Publishers, New Delhi, 2002, pp. 212- 227.

[7]   F. Baker, “Handbook of Bacteriological Technique,” 2nd Edition, Butterwarth and Co. Ltd., London, 1967, pp. 415-421.

[8]   J. Lodder, “The Yeasts,” North-Holland Publishing Co., Amsterdam, 1970, pp. 200-210.

[9]   K. Hace, G. Noskin, K. Traka and S. Hiririchs, “Invasive Infection Due to Candida krusei in Immunocompromised Patients Not Treated with Fluconazole,” Clinical Infectious Diseases, Vol. 20, 1995, pp. 342-347. http://dx.doi.org/10.1093/clinids/20.2.342

[10]   National Committee for Clinical Laboratory Standard, “Reference Method for Broth Dilution Antifungal Susceptibility testing of Yeasts,” Proposed Standard, 2002, M27-A2.

[11]   S. Sandra, P. Rudolph, A. Shawn, J. Richard, J. Daniel and A. Pfaller, “Antifungal Susceptibilities of Candida Species Causing Vulvovaginitis and Epidemiology of Recurrent Cases,” Journal of Clinical Microbiology, Vol. 43, No. 5, 2005, pp. 2155-2162. http://dx.doi.org/10.1128/JCM.43.5.2155-2162.2005

[12]   M. Gonzalez, M. Elizondo and J. Ayala, “Trends in Species Distribution and Susceptibility of Blood Stream Isolates of Candida Collected in Monterrey Mexico to Seven Antifungal Agents,” Journal of Clinical Microbiology, Vol. 46, No. 9, 2008, pp. 2902-2905. http://dx.doi.org/10.1128/JCM.00937-08

[13]   R. Pelletier, J. Peter, C. Antin, M. Gonzalez, L. Wood and T. Walsh, “Emergence of Resistance of Candida albicans to Clotrimazole in HIV Infected Children: In Vitro and Clinical Correlation,” Journal of Clinical Microbiology, Vol. 38, 2002, pp. 1563-1568.

[14]   R. Harvey and J. Myers, “Nosocomial Fungemia in a Large Community Teaching Hospital,” Archives International Medicine, Vol. 147, 1987, pp. 2117-2120. http://dx.doi.org/10.1001/archinte.1987.00370120053011

[15]   B. Ogunbayo, “Isolates of Yeast from Male Contacts of Women with Vaginal Candidosis,” Genitourinary Medi- cine, Vol. 64, 1998, pp. 135-136.

[16]   E. Akortha, O. Chikwe and O. Nwaugo, “Antifungal Resistance among Candida species from Patients with Genitourinary Tract Infection Isolated in Benin City, Edo estate, Nigeria,” African Journal of Microbiology Research, Vol. 3, No.11, 2009, pp. 694-699.

[17]   J. Sobel, H. Wiesentld, M. Marteus, H. Sperling and T. Chu, “Maintenance of Fluconazole Therapy for Recurrent Vulvovaginal Candidiasis,” National England Journal of Medicine, Vol. 351, 2004, pp. 876-883. http://dx.doi.org/10.1056/NEJMoa033114

[18]   M. Ribeiro, R. Dietze, D. Paula, D. Matta and A. Colombo, “Susceptibility Profile of Vaginal Yeast Isolates from Brazil,” Mycopathology, Vol. 151, 2000, pp. 5-10. http://dx.doi.org/10.1023/A:1010909504071

[19]   B. Mathema, E. Cross, E. Dun, S. Park, J. Bedell, B. Slade, L.Williams, L. Reley and D. Perlin, “Prevalence of Vaginal Colonization by Drug Resistant Candida Species in College-Age Women with Previous Exposure to Over-the Counter Azole Antifungals,” Clinical Infectious Diseases, Vol. 33, 2001, pp. 23-27. http://dx.doi.org/10.1086/322600

[20]   M. Pfaller, S. Diekema, L. Messer, R. Boyken and J. Hollis, “Activities of Fluconazole and Varicanazole against 1568 Recent Clinical Isolates of Candida Species Determined by Broth Microdilution Disk Diffusion and Etest Methods: Report from the ARTEMIS Global Antifungal Susceptibility Program, 2001,” Journal of Clinical Microbiology, Vol. 41, 2003, pp. 1440-1446. http://dx.doi.org/10.1128/JCM.41.4.1440-1446.2003

[21]   K. Goa and E. Barrdell, “Fluconazole and Update of Its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Use in Major Superficial and Systemic Mycoses in Immunocompromised Patients,” Drugs, Vol. 50, 1995, pp. 658-690. http://dx.doi.org/10.2165/00003495-199550040-00007

[22]   J. Klastersky, “Prevention and Therapy of Fungal Infec- tion in Cancer Patients,” Support Care Cancer, Vol. 3, No. 6, 1995, pp. 393-410. http://dx.doi.org/10.1007/BF00364979

[23]   M. Pfaller, R. Messer and A. Hajjeh, “Trends in Species Distribution and Susceptibility to Fluconazole among Blood Stream Isolates of Candida Species in United States,” Diagnostic Microbiology Diseases, Vol. 33, 1999, pp. 217-222. http://dx.doi.org/10.1016/S0732-8893(98)00160-6

[24]   T. White, K. Marr and R. Bowden, “Clinical Cellular and Molecular Factors that Contribute to Antifungal Drug Resistance,” Clinical Microbiology Revision, Vol. 11, No. 2, 1998, pp. 382-402.

[25]   S. Redding, G. Smith, M. Farinacci, A. Rinaldi, J. Forthegill, A. Rhine-Chalberg and M. Pfaller, “Resistance of Candida albicans to Fluconazole during Treatment of Oropharyngeal Candidiasis in a Patient with AIDS: Documentation by in Vitro Susceptibility Testing and DNA Subtype Analysis,” Clinical Infectious Diseases, Vol. 18, 1994, pp. 240-242. http://dx.doi.org/10.1093/clinids/18.2.240

[26]   S. Newman, “Clinically Significant Mucosal Candidiasis Resistant to Fluconazole Treatment in Patients with AIDS,” Clinical Infectious Diseases, Vol. 19, 1994, pp. 684-686. http://dx.doi.org/10.1093/clinids/19.4.684

[27]   D. Dixon, M. McNeil, M. Cohen, B. Gellin and J. La Montagne, “Fungal Infections: A Growing Threat,” Public Health Report, Vol. 11, 1996, pp. 226-235.

[28]   D. Grahame-Smith and J. Arsonson, “Oxford Textbook of Clinical Pharmacology and Drug Therapy,” 2nd Edition, Oxford University Press Inc., New York 1992, p. 559.

[29]   D. Law and C. Moore, “High Prevalence of Antifungal resistance in Candida spp. from Patients with AIDS,” Journal of Antimicrobial Chemotherapy, Vol. 34 No. 5, 1994, pp. 659-668. http://dx.doi.org/10.1093/jac/34.5.659

[30]   F. Okungbowa, O. Isuehuemhen and A. Dede, “The Distribution, Frequency of Candida species in the Genitourinary Tract among Symptomatic Individuals in Nigeria Cities,” Revised Iberoam Microbiology, Vol. 20, 2003, pp. 60-63.